Abeona Therapeutics Lands Historic FDA Approval for First Cell-Based Gene Therapy for RDEB
Abeona Therapeutics Inc. has received FDA approval for its groundbreaking gene therapy, ZEVASKYN, marking a historic milestone in the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
2 minutes to read